A. Lusque

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

A. Drilon, J. Neal, H. Wakelee, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry

A. Drilon, H. Wakelee, S. Ou, 2018, Journal of Thoracic Oncology.

Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner

J. Moreaux, M. Lacroix-Triki, J. Choudhary, 2019, Nature Communications.

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.

J. Mazières, G. Favre, I. Rouquette, 2018, Lung cancer.

Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.

J. Mazières, P. Caron, A. Lusque, 2019, Presse medicale.

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism

J. Mazières, G. Favre, E. Clermont-Taranchon, 2016, EMBO molecular medicine.